Contribute Try STAT+ Today

Top of the morning to you, and a fine one it is. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say ‘Every new day should be unwrapped like a precious gift.’ To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Our choice today is vanilla caramel cream. Yum. Meanwhile, here are a few tidbits to help you on your journey today. With any luck, you will conquer the world. In any event, stay safe and stay in touch. …

Moderna (MRNA) plans to spend billions of dollars to boost production of Covid-19 vaccines and potentially triple its yearly output of doses in 2022, as the company seeks to meet rising global demand, The Wall Street Journal writes. The company said it could produce up to 3 billion doses of Covid-19 vaccines in 2022, compared with a projected output of up to 1 billion this year. Moderna said it would make no less than 800 million doses this year, up from a minimum 700 million it had forecast previously.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.